Gary James, DO
Family Medicine · Kimball, MINPI 1255317178
Payments from drug & device makers
Across 381 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- AbbVie$567
- Lilly USA, LLC$435
- Boehringer Ingelheim$368
- Takeda Pharmaceuticals U.S.A., Inc.$315
- Astellas Pharma US Inc$289
- plus $3K from 35 others
What the payments were for
- Food & beverage$5,71597%
- Education$2003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 75 | $1,077 |
| AbbVie(2 entities) | 50 | $567 |
| Lilly USA, LLC | 31 | $435 |
| Boehringer Ingelheim | 20 | $368 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $315 |
| Astellas Pharma US Inc | 8 | $289 |
| Teva Pharmaceuticals USA, Inc. | 15 | $282 |
| Novo Nordisk | 19 | $269 |
| Amarin Pharma, Inc. | 17 | $251 |
| GSK | 14 | $219 |
| Amgen | 13 | $209 |
| Mylan Specialty L.p. | 10 | $170 |
| Otsuka America Pharmaceutical, Inc. | 8 | $160 |
| AstraZeneca | 10 | $153 |
| Johnson & Johnson | 7 | $130 |
| Sanofi-aventis U.S. LLC | 7 | $114 |
| Avanir Pharmaceuticals, Inc. | 5 | $90 |
| Intuitive Surgical | 1 | $73 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $73 |
| Merck | 4 | $64 |
| Novartis | 4 | $63 |
| Lundbeck LLC | 3 | $57 |
| Abbott | 3 | $56 |
| Almatica Pharma LLC | 3 | $48 |
| Biogen | 2 | $36 |
| Exact Sciences | 2 | $35 |
| Bayer | 1 | $31 |
| Eisai Inc. | 2 | $30 |
| Ironshore Pharmaceuticals Inc. | 2 | $30 |
| Adlon Therapeutics L.p. | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| Medtronic | 1 | $24 |
| Alkermes, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Lucid Diagnostics Inc. | 1 | $14 |
| Tris Pharma Inc | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $11 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$5,915 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 122 | $115,491 |
| OzempicSemaglutide | 63 | $76,696 |
| JardianceEmpagliflozin | 50 | $64,790 |
| TrulicityDulaglutide | 36 | $44,255 |
| MounjaroTirzepatide | 38 | $39,970 |
| JanuviaSitagliptin Phosphate | 25 | $39,358 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $36,987 |
| XareltoRivaroxaban | 25 | $21,485 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $16,587 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $13,883 |
| NovologInsulin Aspart | 12 | $8,124 |
| Atorvastatin Calcium | 577 | $7,398 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $5,737 |
| Novolog FlexpenInsulin Aspart | 18 | $5,680 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 200 | $5,592 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,077 | $115,491122 claims |
| Novo NordiskOzempic, Novolog | $269 | $84,82075 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $435 | $84,22574 claims |
| Boehringer IngelheimJardiance | $368 | $64,79050 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $219 | $53,57464 claims |
| MerckJanuvia | $64 | $39,35825 claims |
| Johnson & JohnsonXarelto | $130 | $21,48525 claims |
| AbbVieSynthroid | $567 | $2,14941 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Kimball
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.